for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

3SBio Inc

1530.HK

Latest Trade

6.64HKD

Change

-0.22(-3.21%)

Volume

8,125,000

Today's Range

6.60

 - 

6.87

52 Week Range

6.16

 - 

12.30

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
6.86
Open
6.78
Volume
8,125,000
3M AVG Volume
183.74
Today's High
6.87
Today's Low
6.60
52 Week High
12.30
52 Week Low
6.16
Shares Out (MIL)
2,549.25
Market Cap (MIL)
17,303.36
Forward P/E
10.19
Dividend (Yield %)
--

Next Event

Full Year 2021 3SBio Inc Earnings Release

Latest Developments

More

3Sbio Says Phase III Clinical Trial Of 5% Minoxidil Foam Reached Preset End Point

3Sbio Posts HY Net Profit Attributable RMB898.9 MLN, Increased By 28.0%

3Sbio Says Study On Narfuraphine Hydrochloride Tablets Reached Preset Clinical Study Endpoint

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About 3SBio Inc

3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.

Industry

Biotechnology & Drugs

Contact Info

No. 3 A1, Road 10

Shenyang Economy & Technology

Development Zone

SHENYANG, LIA

110027

China

+86.24.25811820

http://www.3sbio.com

Executive Leadership

Jing Lou

Executive Chairman of the Board, Chief Executive Officer

Zhenping Zhu

President- Research & Development at Sunshine Guojian

Fei Wang

Chief Financial Officer

Dongmei Su

Senior Vice President, General Manager, Executive Director

Yongfu Chen

Vice President - Administration and Construction

Key Stats

2.18 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

4.6K

2019

5.3K

2020

5.6K

2021(E)

6.5K
EPS (CNY)

2018

0.490

2019

0.380

2020

0.330

2021(E)

0.546
Price To Earnings (TTM)
15.12
Price To Sales (TTM)
2.36
Price To Book (MRQ)
1.22
Price To Cash Flow (TTM)
10.72
Total Debt To Equity (MRQ)
22.55
LT Debt To Equity (MRQ)
21.19
Return on Investment (TTM)
6.52
Return on Equity (TTM)
5.40

Latest News

Latest News

BRIEF-3Sbio Inc Says Sunshine Guojian Will Launch Proposed IPO On 13 July

* SUNSHINE GUOJIAN WILL LAUNCH PROPOSED INITIAL PUBLIC OFFERING OF ORDINARY SHARES ON 13 JULY

BRIEF-3SBio Inc Updates On Proposed Spin-Off Of Sunshine Guojian Pharmaceutical (Shanghai)

* 3SBIO INC UPDATES ON PROPOSED SPIN-OFF & LISTING OF SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI)

BRIEF-3Sbio Inc Says Approval Obtained For Inetetamab, First Innovative Anti-Her2 Monoclonal Antibody

* 3SBIO INC - APPROVAL OBTAINED FOR INETETAMAB, FIRST INNOVATIVE ANTI-HER2 MONOCLONAL ANTIBODY

BRIEF-3Sbio Inc Announces Issue Of Eur 320 Mln Zero Coupon Convertible Bonds Due 2025

* ISSUER RECEIVED COMMITMENTS TO SELL EUR157.9 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF EXISTING CONVERTIBLE BONDS

BRIEF-3SBio Says Writ Of Summons Issued By Individual Against Co

* WRIT OF SUMMONS ISSUED BY INDIVIDUAL AGAINST CO Source text for Eikon: Further company coverage:

BRIEF-3SBio Inc Appoints Wang Fei Been As CFO

* WANG FEI BEEN APPOINTED AS CFO Source text for Eikon: Further company coverage:

BRIEF-3Sbio Repurchased Aggregate Principal Amount Of Eur5 Million In Face Value Of Bonds Through Over--Counter Market

* REPURCHASED AN AGGREGATE PRINCIPAL AMOUNT OF EUR5 MILLION IN FACE VALUE OF BONDS THROUGH OVER--COUNTER MARKET Source text for Eikon: Further company coverage:

BRIEF-3Sbio Inc Says Numab Therapeutics Closes Series B Financing

* SUNSHINE GUOJIAN'S PARTNER NUMAB THERAPEUTICS CLOSES SERIES B FINANCING Source text for Eikon: Further company coverage:

BRIEF-3Sbio Inc Says NMPA Approved Clinical Trial Application For Anti-Il-5 Humanized Monoclonal Antibody Injection

* NMPA APPROVES CLINICAL TRIAL APPLICATION FOR ANTI-INTERLEUKIN-5 (IL-5) HUMANIZED MONOCLONAL ANTIBODY INJECTION (“610”) Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

REFILE-BRIEF-3SBio Inc Says Co Buys 3.4 Mln Shares For HK$32.9 Mln

* ON DEC 19, CO REPURCHASED 3.4 MILLION SHARES FOR AGGREGATE PURCHASE PRICE OF HK$32.9 MILLION Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up